[Practical application of recombinant bovine somatotropin: sequelae for man, animal and animal husbandry].
Recombinant Bovine Somtatotropin (r-BST) may be produced commercially in the forseeable future. On the basis of a study of the literature, it may be assumed in all likelihood that administration of r-BST to dairy cows will not have a negative effect on public health. However additional research on potential biological activity of recombinant-BST or its fragments and of somatomedins after oral administration, is advisable. Negative effects on the health, fertility and life-span of animals were not observed so far under experimental conditions but any reference to field situations is absent in the literature. Treatment with r-BST should not be initiated prior to within eighty days after parturition. Administration of r-BST also requires proper management in terms of ration formulation and feeding to ensure maintenance of health and production of dairy cattle. The use of r-BST will result in a less accurate estimation of the breeding potential of selected cows, resulting in a reduction of the genetic improvement of milk production. Increased economic benefits should be obtained on farms having high stocking rates (2.35 dairy cows/ha) compared with those having low stocking rates (1.90), varying with the price of r-BST. It is anticipated that the use of r-BST will have little effect on the reduction of the number of dairy cattle and dairy farms up to 1995.
Kievits
J M
JM
Vakgroep Bedrijfsdiergeneeskunde en Voortplanting, Faculteit Diergeneeskunde, Utrecht.
van Dam
H C
HC
Hessel
H W
HW
Renkema
J A
JA
Brand
A
A
D000822:Animal Husbandry / Q000191:economics*; D000824:Animal Nutritional Physiological Phenomena / Q000187:drug effects; D000818:Animals; D001947:Breeding; D002417:Cattle; D004350:Drug Residues / Q000009:adverse effects; D005260:Female; D005298:Fertility / Q000187:drug effects; D013006:Growth Hormone / Q000008:administration & dosage* / Q000494:pharmacology; D006801:Humans; D007774:Lactation / Q000187:drug effects*; D008660:Metabolism / Q000187:drug effects; D011247:Pregnancy; D011634:Public Health; D011994:Recombinant Proteins / Q000494:pharmacology
D011994:Recombinant Proteins; D013006:Growth Hormone
Praktische toepassing van recombinant bovine somatotropine: gevolgen voor mens, dier en bedrijfsvoering.